Hua Teng, Liu Shuangge, Xin Xiaoyan, Jin Zhishan, Liu Qibin, Chi Shuqi, Wang Xiaoxiao, Wang Hongbo
Department of Gynaecology and Obstetrics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, PR China.
Department of Surgery, Wuhan Pulmonary Hospital, Wuhan 430000, PR China.
Oncotarget. 2016 Dec 20;7(51):85196-85207. doi: 10.18632/oncotarget.13236.
The L1 cell adhesion molecule (L1CAM) extensively participates in nervous system development and the malignant progression of human tumours. The prognostic value of L1CAM for the survival of patients with solid tumours remains controversial. The present meta-analysis was thus performed to highlight the relationship between L1CAM expression and prognosis in cancer patients. Relevant publications were identified after searching several widely used databases, including PubMed, EMBASE and the ISI Web of Science. A fixed-effect or random-effect meta-analytical model was employed to correlate L1CAM expression with different outcome measures in both entire tumours and stratified subgroups. 37 studies in total with 8552 patients were eligible for the final analysis. Combined hazard ratios (HRs) and 95% confidence intervals (CIs) suggested that high L1CAM expression had an unfavourable impact on overall survival (HR=2.06, 95%CI 1.65-2.57, P<0.001), disease-specific survival (HR=2.45, 95%CI 1.48-4.05, P<0.001), disease-free survival (HR=2.42, 95%CI 1.4-4.19, P=0.002) and progression-free survival/recurrence-free survival (HR=2.07, 95%CI 1.41-3.05, P<0.001). Subgroup analysis revealed a similar correlation in most tumour types. Overall, L1CAM might be an effective poor prognostic factor for patients with various tumour types.
L1细胞黏附分子(L1CAM)广泛参与神经系统发育和人类肿瘤的恶性进展。L1CAM对实体瘤患者生存的预后价值仍存在争议。因此,进行了本荟萃分析以突出L1CAM表达与癌症患者预后之间的关系。在检索包括PubMed、EMBASE和ISI科学网在内的几个广泛使用的数据库后,确定了相关出版物。采用固定效应或随机效应荟萃分析模型,将L1CAM表达与整个肿瘤及分层亚组中的不同结局指标相关联。共有37项研究、8552例患者符合最终分析条件。合并风险比(HR)和95%置信区间(CI)表明,L1CAM高表达对总生存(HR=2.06,95%CI 1.65-2.57,P<0.001)、疾病特异性生存(HR=2.45,95%CI 1.48-4.05,P<0.001)、无病生存(HR=2.42,95%CI 1.4-4.19,P=0.002)和无进展生存/无复发生存(HR=2.07,95%CI 1.41-3.05,P<0.001)有不利影响。亚组分析显示,在大多数肿瘤类型中存在类似的相关性。总体而言,L1CAM可能是各类肿瘤患者有效的不良预后因素。